^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGFR-3 inhibitor

    Related drugs:
    3d
    Adebrelimab and famitinib alone or combined with short-course chemotherapy as the first-line treatment for PD-L1-positive advanced non-small cell lung cancer: a clinical study (ChiCTR2500115247)
    P4, N=80, Not yet recruiting, Changzhou First People's Hospital; Changzhou First People's Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    3d
    Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (ChiCTR2500114518)
    P4, N=350, Not yet recruiting, Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University
    New P4 trial
    |
    Sulanda (surufatinib)
    3d
    Phase Ⅱ Clinical Study of Surufatinib Combined with Temozolomide as First-line Therapy for Pulmonary Neuroendocrine Tumors (ChiCTR2600116780)
    P2, N=27, Not yet recruiting, The Second Affiliated hospital of Fujian Medical University; The Second Affiliated hospital of Fujian Medical University
    New P2 trial
    |
    temozolomide • Sulanda (surufatinib)
    3d
    Surufatinib for advanced or metastatic chemotherapy-refractory thymic malignancies: a single-arm, single-center, phase II study (ChiCTR2600116776)
    P2, N=20, Completed, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    Sulanda (surufatinib)
    3d
    Surufatinib combined with toripalimab, albumin - bound paclitaxel and radiotherapy for first - line treatment of advanced esophageal cancer:A single - arm, open - label, phase II clinical study (ChiCTR2600116673)
    P2, N=30, Completed, Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital; The First Medical Center, Chinese
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Sulanda (surufatinib)
    12d
    Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=96, Recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    carboplatin • temozolomide • capecitabine • Sulanda (surufatinib)
    13d
    A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Qinglei Gao
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiRuiYi (fluzoparib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
    18d
    Systemic Therapy for Advanced Pheochromocytoma and Paraganglioma: Real-World Evidence from a Single Center Cohort. (PubMed, Endocr Relat Cancer)
    In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.
    Journal • HEOR • Real-world evidence
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    temozolomide • Sulanda (surufatinib)
    25d
    IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
    P1/2, N=29, Suspended, University of Florida | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HR negative + HER-2 positive
    |
    Tecentriq (atezolizumab) • Fotivda (tivozanib)
    1m
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy (clinicaltrials.gov)
    P2, N=66, Recruiting, Shandong Tumor Hospital
    New P2 trial
    |
    irinotecan • famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    1m
    2023-012-00CH1: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=502, Recruiting, Hutchmed | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> May 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    ZSPAC-17: Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (clinicaltrials.gov)
    P4, N=350, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Sulanda (surufatinib)